| Cohort A (n = 170) | Cohort B (n = 237) | ||
---|---|---|---|---|
Therapy | No. of Patients | % | No. of Patients | % |
Hormone therapy, % | Â | Â | Â | Â |
   Tamoxifen | 65 | 38* | 62 | 26 |
   Medroxyprogesterone acetate | 80 | 47* | 35 | 15 |
   Aromatase inhibitors | 19 | 11* | 130 | 55 |
Chemotherapy, % | Â | Â | Â | Â |
   Anthracyclines | 81 | 48* | 51 | 22 |
   Taxanes | 43 | 25* | 110 | 46 |
   Vinorelbine | 4 | 2.4* | 60 | 25 |
   Capecitabine | 13 | 7.6* | 100 | 42 |
   Mitomycin | 82 | 49* | 2 | 0.8 |
HER2 targeting therapy, % | Â | Â | Â | Â |
   Trastuzumab | 5 | 2.9* | 51 | 22 |